Skip to main content
SpringerLink
Log in

Tissue Protective Activities of Erythropoietin

  • Conference paper
Intensive Care Medicine

  • 2150 Accesses

Abstract

Erythropoietin (EPO) is a 165 amino acid glycoprotein hormone (30.4 kDa) member of the type 1 cytokine superfamily that is produced primarily by renal cortical and outer medullary type 1 fibroblasts [1] in response to tissue hypoxia under the control of the oxygen-sensitive transcription factor hypoxia-inducible factor-l (HIF-l). EPO binds to a preformed EPO receptor homodimer (EPOR)2 present on the cell membrane of erythrocyte progenitors. On activation of (EPOR)2 a molecular cascade begins with the phosphorylation of Janus tyrosine kinase 2, which ultimately results in inhibition of programmed cell death, principally involving Akt and the Bcl-2 gene family, resulting in the survival and maturation of erythroid progenitor cells to erythrocytes [2]. The overall effect is a compensatory adaptation to tissue hypoxia by enhancing the oxygen-carrying capacity of the blood [3], and thus may be therapeutically useful for the treatment of anemia associated with chronic kidney disease or chemotherapy [4–6].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Johnson DW, Forman C, Vesey DA (2006) Novel renoprotective actions of erythropoietin: New uses for an old hormone. Nephrology (Carlton) 11: 306–312

    Article  CAS  PubMed  Google Scholar 

  2. Jelkmann W (1992) Erythropoietin: Structure, control of production, and function. Physiol Rev 72: 449–489

    Google Scholar 

  3. Fisher JW (2003) Erythropoietin: Physiology and pharmacology update. Exp Biol Med (Maywood) 228: 1–14

    CAS  Google Scholar 

  4. Adamson W, Egrie JC, Browne JK, Downing MR, Eschbach W (1988) The use of recombinant human erythropoietin (EPa) to correct the anemia of end-stage renal disease: A progress report. Behring Inst Mitt 188-192

    Google Scholar 

  5. Drueke TB, Locatelli F, Clyne N, et al (2006) Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355: 2071–2084

    Article  CAS  PubMed  Google Scholar 

  6. Oster W, Herrmann F, Gamm H, et al (1990) Erythropoietin for the treatment of anemia of malignancy associated with neoplastic bone marrow infiltration. J Clin Oncol 8: 956–962

    Google Scholar 

  7. Abdelrahman M, Sharples EJ, McDonald MC, et al (2004) Erythropoietin attenuates the tissue injury associated with hemorrhagic shock and myocardial ischemia. Shock 22: 63–69

    Article  CAS  PubMed  Google Scholar 

  8. Calvillo L, Latini R, Kajstura J, et al (2003) Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Nat! Acad Sci USA 100: 4802–4806

    Article  CAS  PubMed  Google Scholar 

  9. Heeschen C, Aicher A, Lehmann R, et al (2003) Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood 102: 1340–1346

    Article  CAS  PubMed  Google Scholar 

  10. Patel NS, Sharples EJ, Cuzzocrea S, et al (2004) Pretreatment with EPa reduces the injury and dysfunction caused by ischemia/reperfusion in the mouse kidney in vivo. Kidney Int 66: 983–989

    Article  CAS  PubMed  Google Scholar 

  11. Sakanaka M, Wen TC, Matsuda S, et al (1998) In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc Nat! Acad Sci USA 95: 4635–4640

    Article  CAS  PubMed  Google Scholar 

  12. Sharples EJ, Patel N, Brown P, et al (2004) Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia-reperfusion. J Am Soc Nephrol 15: 2115–2124

    Article  CAS  PubMed  Google Scholar 

  13. van Wijk SJ, Hageman GJ (2005) Poly(adp-ribose) polymerase-l mediated caspase-indepen dent cell death after ischemia/reperfusion. Free Radic Biol Med 39: 81–90

    PubMed  Google Scholar 

  14. Gourdin MJ, Bree B) De Kock M (2009) The impact of ischaemia-reperfusion on the blood vessel. Eur J Anaesthesiol 26: 537–547

    Article  CAS  PubMed  Google Scholar 

  15. Lenz A, Franklin GA, Cheadle WG (2007) Systemic inflammation after trauma. Injury 38: 1336–1345

    Article  PubMed  Google Scholar 

  16. van Griensven M, Stalp M, Seekamp A (1999) Ischemia-reperfusion directly increases pulmonary endothelial permeability in vitro. Shock 11: 259–263

    Article  PubMed  Google Scholar 

  17. Morishita E, Masuda S, Nagao M, Yasuda Y, Sasaki R (1997) Erythropoietin receptor is expressed in rat hippocampal and cerebral cortical neurons, and erythropoietin prevents in vitro glutamate-induced neuronal death. Neuroscience 76: 105–116

    Article  CAS  PubMed  Google Scholar 

  18. Wright GL, Hanlon P, Amin K, Steenbergen C, Murphy E, Arcasoy MO (2004) Erythropoietin receptor expression in adult rat cardiomyocytes is associated with an acute cardioprotective effect for recombinant erythropoietin during ischemia-reperfusion injury. FASEB J 18: 1031–1033

    CAS  PubMed  Google Scholar 

  19. Depping R, Kawakami K, Ocker H, et al (2005) Expression of the erythropoietin receptor in human heart. J Thorac Cardiovasc Surg 130: 877–878

    Article  PubMed  Google Scholar 

  20. Pars a CJ, Matsumoto A, Kim J, et al (2003) A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest 112: 999–1007

    CAS  PubMed  Google Scholar 

  21. Westenfelder C, Biddle DL, Baranowski RL (1999) Human, rat, and mouse kidney cells express functional erythropoietin receptors. Kidney Int 55: 808–820

    Article  CAS  PubMed  Google Scholar 

  22. Yang CW, Li C, Jung JY, et al (2003) Preconditioning with erythropoietin protects against subsequent ischemia-reperfusion injury in rat kidney. FASEB J 17: 1754–1755

    Article  CAS  PubMed  Google Scholar 

  23. Anagnostou A, Lee ES, Kessimian N, Levinson R, Steiner M (1990) Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc Natl Acad Sci USA 87: 5978–5982

    Article  CAS  PubMed  Google Scholar 

  24. Bahlmann FH, DeGroot K, Duckert T, et al (2003) Endothelial progenitor cell proliferation and differentiation is regulated by erythropoietin. Kidney Int 64: 1648–1652

    Article  CAS  PubMed  Google Scholar 

  25. Aoshiba K, Onizawa S, Tsuji T, Nagai A (2009) Therapeutic effects of erythropoietin in murine models of endotoxin shock. Crit Care Med 37: 889–898

    Article  Google Scholar 

  26. Genc K, Genc S, Baskin H, Semin I (2006) Erythropoietin decreases cytotoxicity and nitric oxide formation induced by inflammatory stimuli in rat oligodendrocytes. Physiol Res 55: 33–38

    Google Scholar 

  27. Cuzzocrea S, Di Paola R, Mazzon E, et al (2006) Erythropoietin reduces the development of nonseptic shock induced by zymosan in mice. Crit Care Med 34: 1168–1177

    Article  Google Scholar 

  28. Cuzzocrea S, Mazzon E, di Paola R, et al (2005) Erythropoietin reduces the degree of arthritis caused by type ii collagen in the mouse. Arthritis Rheum 52: 940–950

    Article  Google Scholar 

  29. Nagai A, Nakagawa E, Choi HB, Hatori K, Kobayashi S, Kim SU (2001) Erythropoietin and erythropoietin receptors in human CNS neurons, astrocytes, microglia, and oligodendrocytes grown in culture. J Neuropathol Exp Neurol 60: 386–392

    CAS  PubMed  Google Scholar 

  30. Sela S, Shurtz-Swirski R, Sharon R, et al (2001) The polymorphonuclear leukocyte—a new target for erythropoietin. Nephron 88: 205–210

    Article  CAS  PubMed  Google Scholar 

  31. Digicaylioglu M, Bichet S, Marti HH, et al (1995) Localization of specific erythropoietin binding sites in defined areas of the mouse brain. Proc Natl Acad Sci USA 92: 3717–3720

    Article  CAS  PubMed  Google Scholar 

  32. Villa P, Bigini P, Mennini T, et al (2003) Erythropoietin selectively attenuates cytokine production and inflammation in cerebral ischemia by targeting neuronal apoptosis. J Exp Med 198: 971–975

    Article  CAS  PubMed  Google Scholar 

  33. Ehrenreich H, Hasselblatt M, Dembowski C, et al (2002) Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 8: 495–505

    CAS  PubMed  Google Scholar 

  34. Minino AM, Anderson RN, Fingerhut LA, Boudreault MA, Warner M (2006) Deaths: Injuries, 2002. Natl Vital Stat Rep 54: 1–124

    Google Scholar 

  35. Shapiro MJ, Gettinger A, Corwin HL, et al (2003) Anemia and blood transfusion in trauma patients admitted to the intensive care unit. J Trauma 55: 269–273

    Article  PubMed  Google Scholar 

  36. Corwin HL, Gettinger A, Rodriguez RM, et al (1999) Efficacy of recombinant human erythropoietin in the critically ill patient: A randomized, double-blind, placebo-controlled trial. Crit Care Med 27: 2346–2350

    Article  CAS  PubMed  Google Scholar 

  37. Corwin HL, Gettinger A, Pearl RG, et al (2002) Efficacy of recombinant human erythropoietin in critically ill patients: A randomized controlled trial. JAMA 288: 2827–2835

    Article  CAS  PubMed  Google Scholar 

  38. Corwin HL, Gettinger A, Fabian TC, et al (2007) Efficacy and safety of epoetin alfa in critically ill patients. N Engl J Med 357: 965–976

    Article  CAS  PubMed  Google Scholar 

  39. Napolitano LM, Fabian TC, Kelly KM, et al (2008) Improved survival of critically ill trauma patients treated with recombinant human erythropoietin. J Trauma 65: 285–297

    Article  CAS  PubMed  Google Scholar 

  40. McCaffery PJ, Fraser JK, Lin FK, Berridge MV (1989) Subunit structure of the erythropoietin receptor. J BioI Chern 264: 10507–10512

    CAS  Google Scholar 

  41. Goodman JW, Hall EA, Miller KL, Shinpock SG (1985) Interleukin 3 promotes erythroid burst formation in “serum-free” cultures without detectable erythropoietin. Proc Nat! Acad Sci USA 82: 3291–3295

    Article  CAS  PubMed  Google Scholar 

  42. Monette FC, Sigounas G (1988) Growth of murine multipotent stem cells in a simple “serumfree” culture system: Role of interleukin-3, erythropoietin, and hemin. Exp Hematol 16: 250–255

    CAS  PubMed  Google Scholar 

  43. Sieff CA, Ekern SC, Nathan DG, Anderson JW (1989) Combinations of recombinant colonystimulating factors are required for optimal hematopoietic differentiation in serum-deprived culture. Blood 73: 688–693

    CAS  PubMed  Google Scholar 

  44. Brines M, Grasso G, Fiordaliso F, et al (2004) Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proc Nat! Acad Sci USA 101: 14907–14912

    Article  CAS  PubMed  Google Scholar 

  45. Jubinsky PT, Krijanovski 01, Nathan DG, Tavernier J, Sieff CA (1997) The beta chain of the interleukin-3 receptor functionally associates with the erythropoietin receptor. Blood 90: 1867–1873

    CAS  PubMed  Google Scholar 

  46. Leist M, Ghezzi P, Grasso G, et al (2004) Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 305: 239–242

    Article  CAS  PubMed  Google Scholar 

  47. Brines M, Patel NS, Villa P, et al (2008) Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. Proc Nat! Acad Sci USA 105: 10925–10930

    Article  CAS  PubMed  Google Scholar 

  48. Lai SY, Childs EE, Xi S, et al (2005) Erythropoietin-mediated activation of jak-stat signaling contributes to cellular invasion in head and neck squamous cell carcinoma. Oncogene 24: 4442–4449

    Article  CAS  PubMed  Google Scholar 

  49. Machtay M, Pajak TF, Suntharalingam M, et al (2007) Radiotherapy with or without erythropoietin for anemic patients with head and neck cancer: A randomized trial of the radiation therapy oncology group (rtog 99–03). Int J Radiat Oncol Biol Phys 69: 1008–1017

    Article  CAS  PubMed  Google Scholar 

  50. Lambin P, Ramaekers BL, van Mastrigt GA, et al (2009) Erythropoietin as an adjuvant treatment with (chemo) radiation therapy for head and neck cancer. Cochrane Database Syst Rev CD006158

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The William Harvey Research Institute, Queen Mary University of London Centre for Translational Medicine and Therapeutics, Barts and The London Charterhouse Square, London, ECIM 6BQ, UK

    N. S. A. Patel & M. M. Yaqoob

Authors
  1. N. S. A. Patel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. M. Yaqoob
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C. Thiemermann
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Intensive Care Erasme Hospital, Université libre de Bruxelles, Route de Lennik 808, 1070, Brussels, Belgium

    Jean-Louis Vincent MD, PhD, FCCM, FCCP (Head) (Head)

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer Science + Business Media Inc.

About this paper

Cite this paper

Patel, N.S.A., Yaqoob, M.M., Thiemermann, C. (2010). Tissue Protective Activities of Erythropoietin. In: Vincent, JL. (eds) Intensive Care Medicine. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-5562-3_30

Download citation

  • DOI: https://doi.org/10.1007/978-1-4419-5562-3_30

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4419-5561-6

  • Online ISBN: 978-1-4419-5562-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation